Repligen Corp. 10-Q Summary: Quarter Ended December 31, 2002
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2002, and the nine-month period ended on that date. Repligen Corporation operates in two primary areas: the sale of specialty pharmaceutical products (Protein A for antibody purification and SecreFlo for diagnostic use) and the development of therapeutic drug candidates for pediatric developmental disorders (autism, mitochondrial disease) and autoimmune disorders (ITP). The company recently launched SecreFlo following FDA approval in April 2002.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2002 | Nine Months Ended Dec 31, 2002 |
|---|---|---|
| Product Revenue | $2,417,030 | $5,723,962 |
| Gross Margin | $1,276,122 (53%) | $3,251,611 (57%) |
| Operating Expenses | $2,182,458 | $6,555,927 |
| Net Loss | $(765,853) | $(2,839,640) |
| Net Loss Per Share | $(0.03) | $(0.11) |
| Cash and Cash Equivalents | $6,025,416 (as of Dec 31, 2002) | |
| Total Marketable Securities | ||
| Working Capital | $17,831,000 (as of Dec 31, 2002) |
Liquidity: Total cash, cash equivalents, and marketable securities totaled approximately $19.9 million at December 31, 2002. The company reported no long-term debt on the balance sheet.
Material Changes vs. Prior Period
- Revenue Growth: Product revenue increased 105% year-over-year for the quarter and 106% for the nine-month period. This growth is driven by the launch of SecreFlo and increased demand for Protein A products from value-added resellers.
- Margin Expansion: Gross margin percentage improved from 50% to 53% for the quarter and from 46% to 57% for the nine-month period, attributed to product mix changes and operational efficiencies.
- Expense Increases: Operating expenses rose 31% for the quarter and 14% for the nine-month period. Research and Development (R&D) increased due to clinical trial costs, while Selling, General, and Administrative (SG&A) expenses rose due to litigation costs, staffing, and relocation to a new corporate headquarters.
- Investment Income: Investment and interest income decreased 46% for the quarter and 49% for the nine-month period due to lower interest rates and reduced average funds available for investment.
Outlook, Risks, and Unusual Items
Management Commentary: Management expects to incur higher operating costs due to expanded R&D for clinical trials and marketing for SecreFlo. The company believes it has sufficient funding to meet working capital and capital expenditure requirements for the next 24 months.
Unusual Items:
- SecreFlo Milestone Payment: In April 2002, the company paid $1.25 million in cash and issued 696,223 shares of common stock (valued at $2.58 million) to ChiRhoClin, Inc. as a milestone payment for FDA approval. These costs were recorded as a long-term intangible asset and are being amortized.
- Capital Expenditures: Cash was reduced by approximately $1.03 million for capital expenditures related to the new corporate headquarters in Waltham, MA.
Risks and Contingencies:
- Legal Proceedings: Repligen is involved in patent litigation with Pro-Neuron, Inc. regarding uridine rights and with Bristol-Myers Squibb Company regarding CTLA4-Ig patent inventorship. A trial against Bristol-Myers Squibb is scheduled for April 2003. Adverse outcomes could restrict commercialization of key drug candidates.
- Customer Concentration: For the nine months ended Dec 31, 2002, two customers accounted for approximately 38% and 30% of total revenues.
- Liquidity Risk: While current funds are deemed sufficient for 24 months, there is no assurance that additional financing will be available on favorable terms if needed.
Key Facts for Investor Verification
- Cash Burn Rate: Verify the sustainability of the current cash position ($19.9M) against the projected 24-month runway given the increased R&D and litigation expenses.
- SecreFlo Commercialization: Assess the actual sales trajectory of SecreFlo post-launch (October 2002) to determine if it meets revenue projections.
- Legal Outcomes: Monitor the April 2003 trial date regarding the CTLA4-Ig patent dispute with Bristol-Myers Squibb, as this is critical for the company's autoimmune drug pipeline.
- Clinical Trial Progress: Track the status of Phase 3 trials for secretin in autism and upcoming trials for uridine in mitochondrial disease and purine autism.
- Customer Dependency: Evaluate the risk associated with the top two customers representing nearly 70% of revenue for the nine-month period.